NASDAQ:ADMA
ADMA Biologics Inc Stock News
$8.81
+1.88 (+27.13%)
At Close: May 10, 2024
Deciphera's (DCPH) Q4 Earnings Miss, Qinlock Drives Revenues
01:43pm, Wednesday, 08'th Feb 2023 Zacks Investment Research
Deciphera (DCPH) reports a wider-than-expected loss per share for the fourth quarter of 2022, while revenues driven by Qinlock sales, beat estimates.
ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA
12:00pm, Wednesday, 08'th Feb 2023 GlobeNewswire Inc.
FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth
Sage and Biogen's NDA for Depression Drug Gets Priority Review
03:17pm, Tuesday, 07'th Feb 2023 Zacks Investment Research
Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review.
Gilead's (GILD) Breast Cancer Drug Trodelvy Gets FDA Nod
06:27pm, Monday, 06'th Feb 2023 Zacks Investment Research
Gilead Sciences, Inc. (GILD) announces the FDA approval of their first-in-class, Trop-2 directed antibody-drug conjugate, Trodelvy, for the treatment of metastatic HR+/HER2- breast cancer in adult pat
Karuna (KRTX) to Obtain Global Rights to Goldfinch's Candidates
02:53pm, Friday, 03'rd Feb 2023 Zacks Investment Research
Karuna Therapeutics (KRTX) announces a definitive agreement with Goldfinch Bio to acquire global rights to the latter's lead clinical-stage candidate, GFB-887 and TRPC4/5 channel candidates.
Biomea (BMEA) Begins Dosing in Lung Cancer Study, Stock Up
04:27pm, Wednesday, 18'th Jan 2023 Zacks Investment Research
Biomea Fusion (BMEA) announces the successful dosing of the first patient in phase I/Ib study of BMF-219 in KRAS mutant solid tumors. Stocks rise 11.69% in response.
ADMA Biologics: FY22 Numbers Key Inflection Point
01:29am, Sunday, 15'th Jan 2023
ADMA Biologics continues to outperform benchmarks, after offering investors a source of tactical alpha across the past 18 months. The market continues to reward its hypothesis in treating primary humo
Jim Cramer Says Forget AT&T, This 'Class Of The Field' Communications Stock Is Better
01:24pm, Tuesday, 10'th Jan 2023 Benzinga
On CNBC’s "Mad Money Lightning Round," Jim Cramer said ADMA Biologics, Inc. (NASDAQ: ADMA) is a "great spec, but it is losing money hand over fist. I think it’s very binary. I can not like binar
Bulls In A Bear Market: These 10 Stocks Clocked Gains In Excess Of 100% In 2022
04:11pm, Saturday, 31'st Dec 2022 Benzinga
2022 would go down as one of the worst years for the financial markets. The sell-off has been all-pervasive, with stocks, bonds and cryptos all selling off indiscriminately. Even as high-fliers like
ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
09:05pm, Friday, 09'th Dec 2022 GlobeNewswire Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicate
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock
01:45pm, Wednesday, 07'th Dec 2022 GlobeNewswire Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicate
ADMA Biologics Announces Proposed Public Offering of Common Stock
09:05pm, Tuesday, 06'th Dec 2022 GlobeNewswire Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicat
ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate
09:01pm, Tuesday, 06'th Dec 2022 GlobeNewswire Inc.
Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
10:10am, Friday, 11'th Nov 2022 Benzinga
Gainers
Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 156.2% to close at $0.2608 on Thursday after dipping 40% on Wednesday. Fast Radius received Bankruptcy court approval of first day motions relat
Why Magnite Shares Are Trading Higher By Over 45%? Here Are 69 Stocks Moving In Thursday's Mid-Day Session
06:05pm, Thursday, 10'th Nov 2022 Benzinga
Gainers
Fast Radius, Inc. (NASDAQ: FSRD) shares climbed 172% to $0.2769 after dipping 40% on Wednesday. Fast Radius received Bankruptcy court approval of first day motions related to the company's vo